Fig. 1

Transcriptomic analysis and immunohistochemistry assay of AHCYL1 in human lung cancer. A Column scatter plot showing the normalized (log2 (normcount + 1)) expression of AHCYL1 mRNA in normal tissue (n = 110) versus primary tumor (n = 1016) (Mann–Whitney Test, p = 0.0008). B IHC analysis of representative tissue samples from normal lung and lung adenocarcinoma tumor stained with an anti-AHCYL1 and Ki67antibodies. Scale bars = 100 µm. Original magnification × 200. C Column scatter plot showing the normalized (log2 (normcount + 1)) expression of AHCYL1 mRNA in primary tumors (n = 13) vs. corresponding recurrence (n = 38) (p = 0.0403) vs. distant metastasis (n = 67) (p = 0.0209) (One-Way ANOVA, Tukey’s multiple comparisons test). D Spearman’s correlation analysis o AHCYL1 expression vs. Ki67 expression (n = 1105; p < 0.0001). E Kaplan–Meier for patients with Low AHCYL1-High Ki67 versus High AHCYL1-Low Ki67 analyzed with Mantel-Cox test (n = 1925; p = 0.00012). F Spearman’s correlation and linear regression analysis of AHCYL1 expression versus stemness score (n = 1105; p < 0.0001). G High AHCYL1 Low Ki67 (n = 279) versus Low AHCYL1 High Ki67 (n = 381) stemness index (RNA expression based) (unpaired T test, p < 0.0001). H High AHCYL1 Low Ki67 (n = 279) versus Low AHCYL1 High Ki67 (n = 381) stemness index (epigenetically regulated RNA expression based) (unpaired T test with Welch correction, p < 0.0001). *p < 0.05, ***p < 0.001, ****p < 0.0001